TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01160731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT00886938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study
Description: Repetitive transcranial magnetic stimulation, pilot study
Study: NCT01478555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV 101
Description: Bromfenac in DuraSite

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV 101
Description: Bromfenac in DuraSite

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV 101
Description: Bromfenac in DuraSite

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISV 101
Description: Bromfenac in DuraSite

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISV 101
Description: Bromfenac in DuraSite
Study: NCT02302456

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
Study: NCT00428168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine
Description: Betahistine 24mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betahistine
Description: Betahistine 24mg BID
Study: NCT03709615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered CBT for social anxiety disorder
Description: An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial.
Study: NCT04020432

Intervention type: BEHAVIORAL
Intervention: questionary
Description: A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally.
Study: NCT00346528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next Generation Ophthalmic Irrigating Solution (NGOIS)
Description: Volume sufficient to irrigate adequately during cataract surgery
Study: NCT00346528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSS Plus
Description: Volume sufficient to irrigate adequately during cataract surgery
Study: NCT00004859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
Study: NCT02542995

Intervention type: OTHER
Group type: OTHER
Intervention: QI interventions
Description: Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
Study: NCT00932464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240-mg oral tablet; single dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240-mg oral tablet; single dose with high-fat breakfast
Study: NCT01059812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected subcutaneously twice daily. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Injected subcutaneously twice daily. Dose was individually adjusted.
Study: NCT04297891

Intervention type: OTHER
Intervention: Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
Description: The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity.

Intervention type: OTHER
Intervention: Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
Description: The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Gen Sequencing (NGS)
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Gen Sequencing (NGS)
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Gen Sequencing (NGS)
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
Study: NCT03663322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT Protocol
Description: Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: OMT-Sham Protocol
Description: Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
Study: NCT02209194

Intervention type: DEVICE
Intervention: E-liac Stent Graft System
Description: Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
Study: NCT04351425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Weaning to crib
Description: We weaned the infants into two groups. Group A, 1.6 kg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weaning to crib
Description: We weaned the infants into two groups. Group A, 1.6 kg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Weaning from incubator
Description: We weaned the infants into two groups. group B, 1.4 kg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weaning from incubator
Description: We weaned the infants into two groups. group B, 1.4 kg
Study: NCT01855035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prolonged ECG monitoring
Description: 10-day Holter ECG measurement

Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
Study: NCT02557347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive fluid management
Description: nursing education, dietary advice, extra hypertonic dialysis cycles
Study: NCT01036009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withdrawal of immunosuppression and donor lymphocyte infusion
Description: Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
Study: NCT01651923

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.

Intervention type: DRUG
Group type: OTHER
Intervention: Heparin
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
Study: NCT03099759

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D2/D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D2/D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D2/D3
Study: NCT04394546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX LAAC Device
Description: WATCHMAN FLX LAAC Device Implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Vitamin K Oral Anticoagulant
Description: Initiation or continuation of a NOAC drug
Study: NCT01203371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftopidil
Description: 0,25 mg (2weeks) and 0,50 mg (10 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0,4 mg/day
Study: NCT03685513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioHPP PEEK-based single posterior crowns
Description: BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
Study: NCT02668406

Intervention type: OTHER
Intervention: Venous blood sampling (2 timepoints) (Phase A and B)
Description: 8.5ml at Day 1 + 8.5ml at Day 5

Intervention type: OTHER
Intervention: Venous blood sampling (1 timepoint) (Phase A and B)
Description: 8.5ml at Day 1

Intervention type: OTHER
Intervention: Voided urine sampling (first sample) (Phase A)
Description: At least 20ml upon confirmation of being part of one of the 3 study groups
Study: NCT03685513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metal ceramic single posterior crowns
Description: Standard metal coping veneered with glass ceramics
Study: NCT00653562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: Oral
Study: NCT01500096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: American ginseng
Description: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: American ginseng
Description: American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for American ginseng
Description: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day
Study: NCT02668406

Intervention type: OTHER
Intervention: Voided urine sampling (first sample) (Phase A)
Description: At least 20ml upon confirmation of being part of one of the 3 study groups

Intervention type: OTHER
Intervention: Voided urine sampling (first sample) (Phase A)
Description: At least 20ml upon confirmation of being part of one of the 3 study groups
Study: NCT01500096

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for American ginseng
Description: Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day
Study: NCT02668406

Intervention type: OTHER
Intervention: Voided urine sampling (second sample) (Phase A)
Description: At least 20ml during routine hospital stay or routine follow-up visit

Intervention type: OTHER
Intervention: Voided urine sampling (second sample) (Phase A)
Description: At least 20ml during routine hospital stay or routine follow-up visit
Study: NCT03435458

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Balloon catheter + oral misoprostol
Description: The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral misoprostol alone
Description: Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
Study: NCT01934699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac ultrasound
Description: Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scanner
Description: Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
Study: NCT00670462

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Description: SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance-Tailored Treatment (MTT)
Study: NCT01562847

Intervention type: DRUG
Intervention: Nilotinib
Description: Patients will be treated with 800 mg nilotinib daily.
Study: NCT04277741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS4 bar
Description: The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control bar
Description: The control group will consume one native wheat starch bar per day.
Study: NCT02971384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinaforce

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Echinaforce
Study: NCT03010189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraphy
Description: A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraphy
Description: A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart-rate variability monitoring
Description: A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart-rate variability monitoring
Description: A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pupillometry
Description: A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
Study: NCT04320095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bizact tonsillectomy device
Description: Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bizact tonsillectomy device
Description: Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bizact tonsillectomy device
Description: Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bizact tonsillectomy device
Description: Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
Study: NCT03431389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy tube
Description: Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
Study: NCT04310228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir Combined With Tocilizumab
Description: Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.~Tocilizumab:The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: The first dose is 4 \~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.
Study: NCT03421080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodGYM
Description: The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MoodGYM
Description: The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking
Description: Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.